Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas, Programa de Pós-Graduação em Saúde Infantil e do Adolescente, Campinas, SP, Brazil; Centro Infantil Boldrini, Departamento de Oncologia, Campinas, SP, Brazil.
St. Jude Children's Research Hospital, Department of Global Medicine, International Outreach Program and Department of Oncology, Memphis, United States; Instituto Pelé Pequeno Príncipe, Programa de Pós-Graduação em Saúde Infantil e do Adolescente, Curitiba, PR, Brazil.
J Pediatr (Rio J). 2018 Jul-Aug;94(4):432-439. doi: 10.1016/j.jped.2017.06.009. Epub 2017 Aug 30.
To evaluate the clinical features associated with adrenocortical hormone overexpression and familial cancer profiling as potential markers for early detection of adrenocortical tumors in children from South and Southeast Brazil.
The clinical manifestations and anthropometric measurements of 103 children diagnosed with adrenocortical tumors were analyzed.
Between 1982 and 2011, 69 girls and 34 boys diagnosed with adrenocortical tumors were followed-up for a median time of 9.0 years (0-34 years). Signs of androgen overproduction alone (n=75) or associated with cortisol (n=18) were present in 90.3%. TP53 p.R337H mutation was found in 90.5% of patients. Stages I, II, III, and IV were observed in 45.6%, 27.2%, 19.4%, and 7.8% of patients, respectively. At diagnosis, there were no significant differences in height (p=0.92) and weight (p=0.22) among children with adrenocortical tumors, but children with virilization alone had significantly higher height-for-age Z-scores (0.92±1.4) than children with hypercortisolism alone or combined (-0.32±1,8; p=0.03). The five-year overall survival was 76.7% (SD±4.2). Patients with advanced-stage disease had a significantly worse prognosis than those with limited disease (p<0.001). During follow-up, ten of 55 p.R337H carrier parents developed cancer, whereas none of the 55 non-carriers did.
Signs of adrenocortical hormone overproduction appear early, even in cases with early-stage. These signs can be identified at the physical examination and anthropometric measurements. In southern Brazil, pediatric adrenocortical tumor is a sentinel cancer for detecting families with germline p.R337H mutation in TP53 gene.
评估与肾上腺皮质激素过表达和家族性癌症特征相关的临床特征,作为巴西南部和东南部儿童肾上腺皮质肿瘤早期检测的潜在标志物。
分析了 103 例经诊断为肾上腺皮质肿瘤的儿童的临床表现和人体测量学测量值。
在 1982 年至 2011 年间,对 69 名女孩和 34 名男孩进行了随访,中位随访时间为 9.0 年(0-34 年)。仅存在雄激素过度产生(n=75)或与皮质醇相关的(n=18)迹象的患者占 90.3%。在 90.5%的患者中发现了 TP53 p.R337H 突变。分别观察到 I 期、II 期、III 期和 IV 期的患者占 45.6%、27.2%、19.4%和 7.8%。在诊断时,肾上腺皮质肿瘤患儿的身高(p=0.92)和体重(p=0.22)之间无显著差异,但仅存在性征过度发育的患儿的身高年龄 Z 评分显著高于仅存在皮质醇过度症或两者合并的患儿(0.92±1.4 比 -0.32±1.8;p=0.03)。五年总生存率为 76.7%(标准差±4.2)。晚期疾病患儿的预后明显差于局限性疾病患儿(p<0.001)。在随访期间,55 名 p.R337H 携带者父母中有 10 人发生了癌症,而 55 名非携带者父母中没有人发生癌症。
即使在早期阶段,肾上腺皮质激素过度产生的迹象也会较早出现。这些迹象可以通过体格检查和人体测量学测量来识别。在巴西南部,小儿肾上腺皮质肿瘤是发现 TP53 基因种系 p.R337H 突变家族的哨点癌症。